Jong Mi Lee, NP
Nurse Practitioner · Palo Alto, CANPI 1134356280
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,786 of the $173,686 with a category attached, or 60.3%. 17 manufacturers reported payments, led by Biogen at 33.7% of the total. Reporting peaked in 2021 at $56,165 and has fallen 53.2% since, to $26,294 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $636.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$59K
- AstraZeneca$25K
- Sanofi$23K
- Amgen$16K
- ANI Pharmaceuticals, Inc.$10K
- EMD Serono, Inc.$10K
- plus $32K from 11 others
What the payments were for
- Consulting fees$44,79626%
- Speaking & faculty fees$104,78660%
- Travel & lodging$18,08410%
- Food & beverage$5,9593%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 79 | $58,598 |
| AstraZeneca | 27 | $25,083 |
| Sanofi | 28 | $23,071 |
| Amgen(2 entities) | 35 | $15,918 |
| ANI Pharmaceuticals, Inc. | 11 | $9,786 |
| EMD Serono, Inc. | 20 | $9,724 |
| E.r. Squibb & Sons, L.L.C. | 9 | $8,160 |
| Bristol Myers Squibb | 25 | $7,991 |
| Novartis | 23 | $7,573 |
| Novartis Pharma AG | 3 | $2,550 |
| Greenwich Biosciences, Inc. | 1 | $1,600 |
| Mallinckrodt Hospital Products Inc. | 4 | $1,517 |
| Genentech USA, Inc. | 2 | $1,470 |
| TG Therapeutics, Inc. | 3 | $421 |
| Johnson & Johnson | 1 | $128 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Sandoz | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$173,686 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 98 | $892,819 |
| VumerityDiroximel Fumarate | 74 | $665,312 |
| TecfideraDimethyl Fumarate | 58 | $525,016 |
| CopaxoneGlatiramer Acetate | 68 | $372,514 |
| MayzentSiponimod | 37 | $339,190 |
| Plegridy PenPeginterferon Beta-1a | 31 | $234,087 |
| AubagioTeriflunomide | 16 | $218,943 |
| Dalfampridine ErDalfampridine | 174 | $55,418 |
| Glatiramer Acetate | 20 | $37,512 |
| Dimethyl Fumarate | 40 | $7,389 |
| FingolimodFingolimod Hcl | 13 | $6,720 |
| Teriflunomide | 58 | $6,386 |
| Baclofen | 116 | $5,228 |
| LyvispahBaclofen | 12 | $3,535 |
| Gabapentin | 125 | $3,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera | $58,598 | $1,190,328132 claims |
| NovartisMayzent | $7,573 | $339,19037 claims |
| SanofiAubagio | $23,071 | $218,94316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Palo Alto
- Carol BarchPalo Alto$76K
- Holly BernalPalo Alto$63K
- Lindsay MartinPalo Alto$37K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.